IE65573B1 - Use of N-myristoyl-(S)-phenylalanine for obtaining medicinal products intended for the treatment of diseases involving myristoylation - Google Patents
Use of N-myristoyl-(S)-phenylalanine for obtaining medicinal products intended for the treatment of diseases involving myristoylationInfo
- Publication number
- IE65573B1 IE65573B1 IE24291A IE24291A IE65573B1 IE 65573 B1 IE65573 B1 IE 65573B1 IE 24291 A IE24291 A IE 24291A IE 24291 A IE24291 A IE 24291A IE 65573 B1 IE65573 B1 IE 65573B1
- Authority
- IE
- Ireland
- Prior art keywords
- myristoyl
- phenylalanine
- treatment
- myristoylation
- diseases involving
- Prior art date
Links
- GFNNQTYRJPFJGX-NRFANRHFSA-N (2s)-3-phenyl-2-(tetradecanoylamino)propanoic acid Chemical compound CCCCCCCCCCCCCC(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 GFNNQTYRJPFJGX-NRFANRHFSA-N 0.000 title claims abstract description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 5
- 230000007498 myristoylation Effects 0.000 title claims description 7
- 201000010099 disease Diseases 0.000 title abstract 2
- 229940126601 medicinal product Drugs 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 6
- 201000011510 cancer Diseases 0.000 claims abstract description 5
- 239000003112 inhibitor Substances 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 3
- 108090000992 Transferases Proteins 0.000 claims description 2
- 102000004357 Transferases Human genes 0.000 claims description 2
- 231100000252 nontoxic Toxicity 0.000 claims description 2
- 230000003000 nontoxic effect Effects 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000030507 AIDS Diseases 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 17
- 230000000694 effects Effects 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- 102000004190 Enzymes Human genes 0.000 description 9
- 108090000790 Enzymes Proteins 0.000 description 9
- 108010016306 Glycylpeptide N-tetradecanoyltransferase Proteins 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 9
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 7
- 230000003013 cytotoxicity Effects 0.000 description 5
- 231100000135 cytotoxicity Toxicity 0.000 description 5
- 230000035800 maturation Effects 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 239000004471 Glycine Substances 0.000 description 4
- 241001529936 Murinae Species 0.000 description 4
- TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 4
- DYUGTPXLDJQBRB-UHFFFAOYSA-N N-myristoylglycine Chemical compound CCCCCCCCCCCCCC(=O)NCC(O)=O DYUGTPXLDJQBRB-UHFFFAOYSA-N 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 230000001131 transforming effect Effects 0.000 description 4
- TWJNQYPJQDRXPH-UHFFFAOYSA-N 2-cyanobenzohydrazide Chemical compound NNC(=O)C1=CC=CC=C1C#N TWJNQYPJQDRXPH-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 235000021360 Myristic acid Nutrition 0.000 description 3
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 241001430294 unidentified retrovirus Species 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 2
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 2
- 229940100514 Syk tyrosine kinase inhibitor Drugs 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- -1 dragdes Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 210000001589 microsome Anatomy 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 2
- 241000212384 Bifora Species 0.000 description 1
- RGJOEKWQDUBAIZ-IBOSZNHHSA-N CoASH Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS)O[C@H]1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-IBOSZNHHSA-N 0.000 description 1
- 102000005870 Coenzyme A Ligases Human genes 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 description 1
- 108010049894 Cyclic AMP-Dependent Protein Kinases Proteins 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-Phenylalanine Natural products OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 108010011449 Long-chain-fatty-acid-CoA ligase Proteins 0.000 description 1
- 108010038807 Oligopeptides Chemical class 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- PMZXXNPJQYDFJX-UHFFFAOYSA-N acetonitrile;2,2,2-trifluoroacetic acid Chemical compound CC#N.OC(=O)C(F)(F)F PMZXXNPJQYDFJX-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- RGJOEKWQDUBAIZ-UHFFFAOYSA-N coenzime A Natural products OC1C(OP(O)(O)=O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-UHFFFAOYSA-N 0.000 description 1
- 239000005516 coenzyme A Substances 0.000 description 1
- 229940093530 coenzyme a Drugs 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- KDTSHFARGAKYJN-UHFFFAOYSA-N dephosphocoenzyme A Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 KDTSHFARGAKYJN-UHFFFAOYSA-N 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 159000000002 lithium salts Chemical class 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000004452 microanalysis Methods 0.000 description 1
- 229940105132 myristate Drugs 0.000 description 1
- 125000001419 myristoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- DUAFKXOFBZQTQE-QSGBVPJFSA-N myristoyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)CCCCCCCCCCCCC)O[C@H]1N1C2=NC=NC(N)=C2N=C1 DUAFKXOFBZQTQE-QSGBVPJFSA-N 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 210000004765 promyelocyte Anatomy 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000011537 solubilization buffer Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000006190 sub-lingual tablet Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/005—Enzyme inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9000834A FR2657259A1 (fr) | 1990-01-25 | 1990-01-25 | Utilisation de la n-myristoyl-(s)-phenylalanine pour l'obtention de medicaments destines au traitement des maladies faisant intervenir la myristoylation. |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IE910242A1 IE910242A1 (en) | 1991-07-31 |
| IE65573B1 true IE65573B1 (en) | 1995-11-01 |
Family
ID=9393082
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IE24291A IE65573B1 (en) | 1990-01-25 | 1991-01-24 | Use of N-myristoyl-(S)-phenylalanine for obtaining medicinal products intended for the treatment of diseases involving myristoylation |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US5164414A (enExample) |
| EP (1) | EP0443891B1 (enExample) |
| JP (1) | JPH0717503B2 (enExample) |
| AT (1) | ATE94387T1 (enExample) |
| AU (1) | AU633395B2 (enExample) |
| CA (1) | CA2034861A1 (enExample) |
| DE (1) | DE69100364T2 (enExample) |
| DK (1) | DK0443891T3 (enExample) |
| ES (1) | ES2060310T3 (enExample) |
| FR (1) | FR2657259A1 (enExample) |
| IE (1) | IE65573B1 (enExample) |
| OA (1) | OA09478A (enExample) |
| PT (1) | PT96571A (enExample) |
| ZA (1) | ZA91574B (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2672598A1 (fr) * | 1991-02-11 | 1992-08-14 | Adir | Nouveaux inhibiteurs de n-myristoyltransferase, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
| US5859052A (en) * | 1993-01-14 | 1999-01-12 | G. D. Searle & Co. | Fatty acid analogs and prodrugs |
| US5599947A (en) * | 1993-01-14 | 1997-02-04 | G. D. Searle & Co. | Fatty acid analogs and prodrugs |
| US6127393A (en) * | 1995-12-29 | 2000-10-03 | Novactyl, Inc. | Antiproliferative, antiinfective, antiinflammatory, autologous immunization agent and method |
| US6407125B1 (en) | 1995-12-29 | 2002-06-18 | Novactyl, Inc. | Pharmacological agent and method of treatment |
| US6579891B1 (en) | 1995-12-29 | 2003-06-17 | Novactyl, Inc. | Agent and method for prevention and treatment of cancer in animals |
| US6743771B2 (en) | 1995-12-29 | 2004-06-01 | Novactyl, Inc. | Methods and compositions for controlling protein assembly or aggregation |
| US6441009B1 (en) | 1998-08-01 | 2002-08-27 | Novactyl, Inc. | Agent and method of preventing and treating heavy metal exposure and toxicity |
| JP2003514855A (ja) * | 1999-10-13 | 2003-04-22 | チャコン，マルコ，エー． | カロリー制限の効果を模倣した治療的介入 |
| US6403618B1 (en) | 2000-02-15 | 2002-06-11 | Novactyl, Inc. | Agent and method for controlling angiogenesis |
| US20030022938A1 (en) * | 2001-06-25 | 2003-01-30 | Burstein Sumner H. | N-fatty acid-amino acid conjugates and therapeutic uses |
| DE10353806A1 (de) * | 2003-11-14 | 2005-07-07 | Bundesrepublik Deutschland, vertreten durch das Bundesministerium für Gesundheit, dieses vertreten durch das Robert-Koch-Institut, vertreten durch seinen Präsidenten | Verwendung von Aminosäure- und Zucker-Amphiphilen zur Inaktivierung von lipidumhüllten Viren |
| US7544714B2 (en) * | 2004-07-16 | 2009-06-09 | University Of Massachusetts | Lipid-amino acid conjugates and methods of use |
| IL172896A0 (en) * | 2005-12-29 | 2006-06-11 | Yeda Res & Dev | Cxcr4 inhibition |
| AU2012286542A1 (en) | 2011-07-22 | 2014-02-06 | Pacylex Pharmaceuticals Inc. | Synthetic lethality and the treatment of cancer |
| US10201175B2 (en) | 2012-03-30 | 2019-02-12 | Givaudan Sa | N-acylated 1-aminocycloalkyl carboxylic acids as food flavouring compounds |
| CA2868077C (en) | 2012-03-30 | 2020-09-29 | Givaudan S.A. | Powder flavour composition |
| KR102045589B1 (ko) | 2012-03-30 | 2019-11-15 | 지보당 에스아 | 식품 향미 화합물로서의 n-아실-아미노산 유도체 |
| WO2013149019A1 (en) | 2012-03-30 | 2013-10-03 | Givaudan S.A. | N-acylated methionine derivatives as food flavouring compounds |
| CN104219965B (zh) | 2012-03-30 | 2018-10-12 | 奇华顿股份有限公司 | 作为食品加香化合物的γ氨基-丁酸和β丙氨酸的N-酰基衍生物 |
| EP2833739B1 (en) | 2012-03-30 | 2020-12-02 | Givaudan SA | N-acyl proline derivatives as food flavouring compounds |
| JP6224072B2 (ja) | 2012-03-30 | 2017-11-01 | ジボダン エス エー | フレーバープロフィール食用組成物の改良のためのｎ−アシル−アミノ酸誘導体 |
| NZ707090A (en) * | 2012-10-30 | 2019-03-29 | Pacylex Pharmaceuticals Inc | Synthetic lethality and the treatment of cancer |
| WO2015050537A1 (en) | 2013-10-02 | 2015-04-09 | Givaudan S.A. | Organic compounds |
| EP3057444B1 (en) | 2013-10-02 | 2017-12-06 | Givaudan SA | Organic compounds having taste-modifying properties |
| WO2015050535A1 (en) | 2013-10-02 | 2015-04-09 | Givaudan S.A. | Organic compounds |
| GB201317424D0 (en) | 2013-10-02 | 2013-11-13 | Givaudan Sa | Improvements in or relating to organic compounds |
| EP3057445B1 (en) | 2013-10-02 | 2018-07-04 | Givaudan SA | Organic compounds having taste-modifying properties |
| CN105636459A (zh) | 2013-10-02 | 2016-06-01 | 奇华顿股份有限公司 | 有机化合物 |
| CN105592719B (zh) | 2013-10-02 | 2020-03-10 | 奇华顿股份有限公司 | 有机化合物 |
| CN105636934B (zh) | 2013-10-02 | 2019-03-29 | 奇华顿股份有限公司 | N-酰化的2-氨基异丁酸化合物和包含它们的香味组合物 |
| EP3325662B1 (en) | 2015-07-17 | 2023-08-30 | Pacylex Pharmaceuticals Inc. | Epigenetic silencing of nmt2 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4778878A (en) * | 1986-08-07 | 1988-10-18 | Washington University | Novel inhibitor peptides I |
| US4778877A (en) * | 1986-08-07 | 1988-10-18 | Washington University | Novel inhibitor peptides II |
-
1990
- 1990-01-25 FR FR9000834A patent/FR2657259A1/fr active Granted
-
1991
- 1991-01-24 US US07/645,124 patent/US5164414A/en not_active Expired - Fee Related
- 1991-01-24 PT PT96571A patent/PT96571A/pt not_active Application Discontinuation
- 1991-01-24 CA CA002034861A patent/CA2034861A1/fr not_active Abandoned
- 1991-01-24 IE IE24291A patent/IE65573B1/en not_active IP Right Cessation
- 1991-01-24 JP JP3007188A patent/JPH0717503B2/ja not_active Expired - Lifetime
- 1991-01-25 DK DK91400163.1T patent/DK0443891T3/da active
- 1991-01-25 AT AT91400163T patent/ATE94387T1/de active
- 1991-01-25 DE DE91400163T patent/DE69100364T2/de not_active Expired - Fee Related
- 1991-01-25 ES ES91400163T patent/ES2060310T3/es not_active Expired - Lifetime
- 1991-01-25 ZA ZA91574A patent/ZA91574B/xx unknown
- 1991-01-25 AU AU69987/91A patent/AU633395B2/en not_active Ceased
- 1991-01-25 OA OA59940A patent/OA09478A/xx unknown
- 1991-01-25 EP EP91400163A patent/EP0443891B1/fr not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| FR2657259A1 (fr) | 1991-07-26 |
| FR2657259B1 (enExample) | 1994-08-19 |
| ES2060310T3 (es) | 1994-11-16 |
| CA2034861A1 (fr) | 1991-07-26 |
| OA09478A (fr) | 1992-11-15 |
| ATE94387T1 (de) | 1993-10-15 |
| US5164414A (en) | 1992-11-17 |
| JPH0717503B2 (ja) | 1995-03-01 |
| DE69100364D1 (de) | 1993-10-21 |
| AU633395B2 (en) | 1993-01-28 |
| PT96571A (pt) | 1991-10-15 |
| IE910242A1 (en) | 1991-07-31 |
| AU6998791A (en) | 1991-08-01 |
| DE69100364T2 (de) | 1994-04-21 |
| EP0443891A1 (fr) | 1991-08-28 |
| EP0443891B1 (fr) | 1993-09-15 |
| DK0443891T3 (da) | 1993-12-27 |
| ZA91574B (en) | 1991-11-27 |
| JPH04210916A (ja) | 1992-08-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IE65573B1 (en) | Use of N-myristoyl-(S)-phenylalanine for obtaining medicinal products intended for the treatment of diseases involving myristoylation | |
| Saari et al. | 2-Pyridinone derivatives: a new class of nonnucleoside, HIV-1-specific reverse transcriptase inhibitors | |
| TAKE et al. | Comparative studies of the inhibitory properties of antibiotics on human immunodeficiency virus and avian myeloblastosis virus reverse transcriptases and cellular DNA polymerases | |
| HU207298B (en) | Process for producing perhydro-izoquinolin-amino-acid derivatives and pharmaceutical compositions containing them | |
| ITMI950812A1 (it) | Pirril-(indolil)-aril-sulfoni e relativo processo di produzione ed impiego nella terapia delle infezioni da virus dell'aids | |
| IE920444A1 (en) | New n-myristoyltransferase inhibitors, process for preparing¹these and pharmaceutical compositions containing them | |
| US20060205705A1 (en) | Hsp90 inhibitors, methods of making and uses therefor | |
| JPH1081653A (ja) | シス−オレフィン化合物およびその製法 | |
| Gottlieb et al. | Inhibition of protein kinase C by a peptide conjugate homologous to a domain of the retroviral protein p15E. | |
| Zhang et al. | Inhibition of macrophage migration inhibitory factor (MIF) tautomerase activity by dopachrome analogs | |
| Tsunawaki et al. | Relationships of p40 phox with p67 phox in the activation and expression of the human respiratory burst NADPH oxidase | |
| Dormán | Photoaffinity labeling in biological signal transduction | |
| US6376468B1 (en) | Protein:prenyl transferase inhibitors | |
| US6943170B2 (en) | N-cycloalkylglycines as HIV protease inhibitors | |
| Boutin et al. | N‐Myristoyl‐transferase activity in cancer cells: Solubilization, specificity and enzymatic inhibition of a N‐Myristoyl transferase from L1210 microsomes | |
| Chang et al. | Synthesis and antiviral activity of amino acid carbamate derivatives of AZT | |
| US20080199897A1 (en) | Class ii histone deacetylase whole cell enzyme assay | |
| KR0140308B1 (ko) | 항 에이즈 효과를 갖는 hiv 프로테아제 억제제 | |
| HUP9904143A2 (hu) | (4R,5S,6S,7R)-Hexahidro-1-[5-(3-aminoindazol)metil]-3-butil-5,6-dihidroxi-4,7-bisz[fenilmetil]-2H-1,3-diazepin-2-on és felhasználása HIV-proteáz inhibitorként | |
| US20060019951A1 (en) | Vacuolins | |
| US20060128634A1 (en) | Alpha, alpha-disubstituted benzylglycine derivatives as HIV protease inhibitors | |
| Zurzolo et al. | Lipid-tagged proteins | |
| Mainkar et al. | Peptidomimetics: Current and Future Perspectives on HIV Protease Inhibitors | |
| JP3406334B2 (ja) | チロシン特異的リン酸化酵素阻害剤及び制癌剤 | |
| WO2000053577A1 (en) | Hydrazide inhibitors of hiv-1 integrase |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Patent lapsed |